Cargando…
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
Individual or combinations of somatic mutations found in genes from colorectal cancers can redirect the effects of chemotherapy and targeted agents on cancer cell survival and, consequently, on clinical outcome. Novel therapeutics with mechanisms of action that are independent of mutational status w...
Autores principales: | Oberst, Michael D, Fuhrmann, Stacy, Mulgrew, Kathy, Amann, Maria, Cheng, Lily, Lutterbuese, Petra, Richman, Laura, Coats, Steve, Baeuerle, Patrick A, Hammond, Scott A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622052/ https://www.ncbi.nlm.nih.gov/pubmed/25484061 http://dx.doi.org/10.4161/19420862.2014.975660 |
Ejemplares similares
-
The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
por: Peng, Li, et al.
Publicado: (2012) -
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110
por: Deisting, Wibke, et al.
Publicado: (2015) -
Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016) -
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
por: Gonzalez-Exposito, Reyes, et al.
Publicado: (2019) -
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
por: Bacac, Marina, et al.
Publicado: (2016)